Adlego
  • Home
  • About Us
  • News
  • Publications
  • Services
  • Contact Us
Select Page

Strong tumor MR contrast enhancement with novel nanomaterial in an oncogene-driven breast cancer model

by Adlego | Mar 10, 2014 | Interesting Reading

PDF version of article.

Recent News Articles

  • Combination therapy of tumors

  • Kanceras HDAC6-projekt tilldelas anslag från Vinnova

  • The true value of a good partnership!

  • Adlego is testing OsteoDex in an in-vivo model of breast cancer!

  • Drugs for treatment of colorectal cancer, identified with use of three-dimensional cell culture-based screening, was validated in-vivo by Adlego!

Recent Publications

  • Adlego is testing OsteoDex in an in-vivo model of breast cancer!

  • Strong tumor MR contrast enhancement with novel nanomaterial in an oncogene-driven breast cancer model

  • Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

  • AParaDDisE – Anti-Parasitic Drug Discovery in Epigenetics

  • Näsdroppar mot kikhosta väcker intresse

About Adlego

Adlego Biomedical AB is a privately owned company which is focused on drug development. Because Adlego is not liaised with any pharmaceutical company or other CROs, customers are always guaranteed honest project discussions and reports. Medical Product Agencies rely on the independence and integrity of Adlego!

Contact us

Phone: + 46 (0)733 42 17 37

E-mail: info@adlego.se

Address:

Adlego Biomedical AB
Box 42
751 03 Uppsala
Sweden

Twitter

Tweets by @AdlegoB

Site Links

  • Home
  • About Us
  • News
  • Publications
  • Services
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Twitter

© Adlego Biomedical | 2019